Nektar Therap (NKTR.US) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Nov28

Citi initiates coverage of Nektar Therapeutics with a Buy rating and sets a $102 price target

13:02

Nov17

William Blair Maintains Hold Rating on NKTR

23:26

Nov11

H.C. Wainwright Reiterates Buy Rating on Nektar Therapeutics

12:02

Nov7

Nektar Therapeutics released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 33.43 M and actual EPS of USD -8.4458

00:00

Nektar Therapeutics released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 11.79 M (forecast USD 10.2 M), actual EPS USD -1.8748 (forecast USD -2.6065)

00:00

Oct30

Nektar Therapeutics to Release FY2025 Q3 Earnings on November 6 After-Market (EST), Forecast Revenue USD 10.2 M, EPS USD -2.6065

00:51